Products, Services, and Technologies for a Safer, Healthier World Products, Services, and Technologies for a Safer, Healthier World 2013 Interim Financial Results Water-based, clean technology 8 August 2013 solutions for a safer, healthier world
Disclaimer This presentation is personal to the recipient and has been prepared by and is the sole responsibility of PuriCore plc (the "Company"). It is solely for use at a presentation to analysts and potential investors in relation to the proposed placing and open offer of ordinary shares of the Company ("Ordinary Shares"). Some of the information in this document is still in draft form and will only be finalised in the prospectus to be published by the Company in due course (the "Prospectus"). This document is an advertisement and not a prospectus and investors should not subscribe for or purchase any Ordinary Shares except on the basis of information in the Prospectus. The information contained in this document and communicated verbally to you including the speeches of the presenter(s), the question and answer session and any materials distributed at or in connection with it (together the "Presentation" ) is confidential and is being supplied in the United Kingdom only to persons with professional experience in matters relating to investments and/or to high net worth companies as described in Articles 19(5) and 49(2) respectively of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI. 2005/No. 1529) (as amended) made pursuant to section 21(5) of the Financial Services and Markets Act 2000 and, if permitted by applicable law, is being supplied outside the United Kingdom to professionals or institutions whose ordinary business involves them in investment activities. The information contained in this document is not intended to be viewed by, or distributed or passed on (directly or indirectly) to, any other class of persons. No representation or warranty, express or implied, is made as to and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinions contained in the Presentation. The information in this presentation may be subject to verification, completion and change. No liability is accepted for any such information or opinions by the Company or Nomura Code Securities Limited or any of their respective directors, members, officers, employees, agents or advisers. The Company is under no obligation to update or keep current the information contained in this presentation or to correct any inaccuracies which may become apparent, and any opinions expressed in it are subject to change without notice. None of the Company nor Nomura Code Securities Limited nor any of their respective members, directors, officers or employees nor any other person accepts any liability whatsoever for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection therewith. You should not base any behaviour in relation to any securities or investments on this information until after it is made publicly available by the Company or its advisers. Any dealing or encouraging others to deal on the basis of such information may amount to insider dealing under the Criminal Justice Act 1993 and market abuse under the Financial Services and Markets Act 2000. This Presentation includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding the Company and its subsidiary undertakings’ (the “Group”) financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to the Group's products and services), the benefits of and opportunities that may arise as a result of the proposed transactions described in this presentation, timing of regulatory approvals, market opportunities and costs associated with programmes and studies, and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Group's control that could cause the actual results, performance or achievements of the Group to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Group's present and future business strategies and the environment in which the Group will operate in the future. Numerous factors, including those detailed from time-to-time in the Company’s filings with the UK Listing Authority, and in any filings, if applicable, with the Securities and Exchange Commission, may cause results to differ materially from those anticipated in the forward-looking statements. These forward-looking statements speak only as at the date of this Presentation. The Group expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in the Presentation to reflect any change in the Group's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statement. By attending this presentation and/or accepting a copy of this document, you agree to be bound by the foregoing limitations and conditions and, in particular, will be taken to have represented, warranted and undertaken that: (i) you have read and agree to comply with the contents of this notice including, without limitation, the obligation to keep this document and its contents confidential; and (ii) you will not at any time have any discussion, correspondence or contact concerning the information in this document or the offer of Ordinary Shares with any of the Company's suppliers, customers, subcontractors or any governmental or regulatory body without the prior written consent of the Company. Neither this document nor any accompanying document is an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration under the US Securities Act of 1933, as amended (the ‘‘ US Securities Act ’’ ) or an exemption from registration. Neither the existing Ordinary Shares, nor the New Ordinary Shares nor the Open Offer Entitlements have been or will be registered under the US Securities Act or under the securities laws of any state of the United States, or under the applicable securities laws of Australia, Canada or Japan. Subject to certain exceptions, the New Ordinary Shares made available under the Placing and Open Offer and the Open Offer Entitlements may not be offered, sold, taken up, delivered or transferred in or into the United States, Australia, Canada or Japan, and, subject to certain exceptions, white Application Forms are not being posted to and no Open Offer Entitlements will be credited to a stock account of any person with a registered address in the United States, Australia, Canada or Japan. Outside the United States, the New Ordinary Shares and Open Offer Entitlements may not be offered, sold, taken up, delivered or transferred except in an ‘‘ offshore transaction ’’ (as defined in Rule 902(k) under the US Securities Act) in accordance with Rule 903 or Rule 904 of Regulation S under the US Securities Act. 2
H1 Highlights • EBITDA profitability maintained in all business divisions • Group revenue decreased 4.9% (4.1% at constant currency) to $24.1m (H1 2012: $25.3m) � Endoscopy revenue up 1.7% (3.9% at constant currency) to $11.8m (H1 2012: $11.6m) � Supermarket Retail revenue down 19.0% to $10.6m (H1 2012: $13.0m) � Wound Care revenue up 148.0% to $1.7m (H1 2012: $0.7m) � Q2 revenue increased 19.4% (20.5% at constant currency) to $13.2m (Q2 2012: $11.1m) • Gross profit margin strengthened to 33.7% (H1 2012: 33.0%) • Operating expenses decreased 2.9% to $9.0m (H1 2012: $9.2m) • Loss per share (after deduction for extraordinary item) of $0.03 (H1 2013: $0.06) • $13.5m ProduceFresh agreement with a top-3 US retailer (revenue starting late H2 2013) • $14.0m Sterilox Fresh agreement with a top-5 US retailer (revenue starting in Q2 2013) • Marketing partnership with Onset Dermatologics for new Vashe-based dermatologic products • Marketing partnership with SteadMed Medical for Vashe Wound Therapy in the US, Canada, and Mexico • US FDA clearance for Vashe Skin and Wound Hydrogel: itch related to atopic dermatitis 3
Recommend
More recommend
